Latest Biotechnology, Pharmaceutical and Healthcare News

03:06 EDT 30th March 2015 | BioPortfolio

Showing News Articles 1–25 of 400,000+

Monday 30th March 2015

Enzyme Keeps Blood Stem Cells Functional to Prevent Anemia

The study from the Sauer lab brings scientists closer to improving therapies for diseases such as bone marrow failure syndrome, anemia, leukemia, lymphoma and immunodeficiences.

Team Breaks Imaging Barrier

The study from the Carragher lab reveals individual water molecules in a protein complex.

Cells You Can See: A Profile of Art Olson

The Olson lab creates models and computer programs to help scientists visualize cells, viruses and other biological players.

US Capitol Capsule: Obama superbug attack plan hinges on funding, cooperation

President Barack Obama on 27 March unveiled an aggressive five-year plan to combat the growing scourge of superbugs, which infect about 2 million Americans each year, killing 23,000.

French and Benelux stocks-Factors to watch on March 30

PARIS, March 30 (Reuters) - Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

BRIEF-Stallergenes announces approval in Japan of STG320

* Stallergenes announces the approval in Japan of STG320, a sublingual immunotherapy tablet for the treatment of house dust mite allergy

Swiss stocks - Factors to watch on March 30

ZURICH, March 30 (Reuters) - The Swiss blue-chip SMI was seen opening 0.3 percent higher at 9,109 points on Monday, according to premarket indications by bank Julius Baer .

STALLERGENES ANNOUNCES THE APPROVAL IN JAPAN OF STG320, THE FIRST SUBLINGUAL IMMUNOTHERAPY TABLET FOR THE TREATMENT OF HOUSE DUST MITE ALLERGY

STG320 is the first house dust mite immunotherapy tablet ever to obtain a Marketing Authorization in the world Regulatory News: STALLERGENES S.A. (Paris:GENP), a global healthcare company speciali...

Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab

If authorized, Biogen will market and manufacture SB2 in Europe Biogen (NASDAQ: BIIB) today announced the Marketing Authorization Application (MAA) for SB2, its biosimilar infliximab candidate usi...

Cell Therapy Catapult Signs Multiple Collaboration Agreements

New programmes aim to accelerate regenerative medicine The Cell Therapy Catapult has announced four separate collaborations with multiple-partners to deliver health and wealth to the UK through support from Innovate UK, formerly the Technology Strategy Board. The agreement with Plasticell is a further investment in a therapeutic programme util...

Solasia Acquires Exclusive License and Distribution Rights From Camurus for episil® Oral Liquid in Japan and China

Camurus AB (“Camurus”) and Solasia Pharma K.K. (“Solasia”) jointly announced today that they have entered into a license and distribution agreement for episil® oral liquid, a unique and effective treatment for the pain of oral mucositis, a treatment-limiting side effect of some cancer therapies, as well as other oral lesions. As part of t...

BRIEF-Hybrigenics launches 7 million euro capital increase

* Launches 7 million euro ($7.60 million) capital increase without preferential subscription rights

Sanofi chairman says acquisitions not 'indispensable' for future

PARIS (Reuters) - French pharmaceutical company Sanofi has examined acquisitions opportunities but does not view deal-making as "indispensable" to its future, its chairman told French paper Les Echos in an interview.

Hamburg's farewell message: Strengthen, don't undermine, FDA

"It is hard to overstate the unique and vital importance of this agency for all of us," Dr Hamburg said during a speech at the National Press Club in Washington.

PRESS DIGEST- New York Times business news - March 30

March 30 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.

BRIEF-Nicox FY revenue rises to 6.0 million euros

* 2014 revenue 6.0 million euros ($6.52 million) versus 0.4 million euros in 2013

Morphosys: Der endgültige K.O.

Im Dezember wurde das Vertrauen in Morphosys durch den Stopp in der Entwicklung eines Alzheimer-Medikaments angeknockt, nun dürfte das überraschende Ende der Partnerschaft mit Celgene endgültig für...

Morphosys - noch schlechter geht es nicht mehr

Gewinne laufen lassen, Verluste begrenzen - lautet eine bekannte Börsenweissheit. Klingt zunächst einfach und recht logisch, in der Praxis sieht die Sache aber vielfach anders aus. Denn es gilt zw...

BRIEF-Novartis says to make payment of $200 mln to Aduro

* Says accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group.

BRIEF-PledPharma: Phase IIb study - PledOx reduces nerve damage in conjunction with chemotherapy by 43 pct

* Presents top-line results from its phase IIb study - PledOx

BRIEF-Cardio3 Biosciences successfully completes futility analysis of C-Cure

* DSMB recommends continuation of phase 3 study into treatment of congestive heart failure

BRIEF-Formycon FY net result swings to profit of 0.86 mln euros

* FY sales revenue and other income totaling 12.67 million euros ($13.76 million) (prior year: 0.41 million euros)

Novartis Bets $250M-Plus on Aduro’s Immuno-Oncology Work

How bullish are big drugmakers on cancer immunotherapy these days? Take a read from the deal Novartis announced today with Berkeley, CA-based Aduro Biotech, which is getting a nine-figure check from the Swiss drug giant for an immunotherapy approach ...

Aduro Biotech Establishes Major Collaboration with Novartis for Global Research, Development and Commercialization of Immuno-Oncology Products Derived from its Proprietary STING-Targeted CDN Platform Technology

- Aduro to Receive $200M Upfront, Equity Stake and Future Potential Milestones Collectively Totaling up to $750M, Plus Profit Sharing in the Collaboration Aduro Biotech, Inc. today announced the establishment of a major collaboration with Novartis for the worldwide research, development and commercialization of novel immuno-oncology products derived fr...

MorphoSys-Aktie: Fairer Wert aktuell nur noch bei 70 bis 75 Euro - Aktienanalyse

Berlin - MorphoSys-Aktienanalyse von "Heibel-Ticker": Stephan Heibel, Aktienexperte von "Heibel-Ticker", nimmt in einer aktuellen Aktienanalyse die Aktie des Biotech-Unternehmens MorphoSys AG (ISIN...


Search BioPortfolio:
Loading
Advertisement
Advertisement

BioPortfolio's biotechnology, pharmaceutical, healthcare and medical device information service collates press releases, news articles and blogs from over 275 sources.